Invention Grant
- Patent Title: Use of ADCC-optimized antibodies for treating weak patients
-
Application No.: US12659824Application Date: 2010-03-23
-
Publication No.: US08501171B2Publication Date: 2013-08-06
- Inventor: Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
- Applicant: Dominique Bourel , Sylvie Jorieux , Christophe De Romeuf , Philippe Klein , Christine Gaucher , Nicolas Bihoreau , Emmanuel Nony
- Applicant Address: FR Les Ulis
- Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
- Current Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
- Current Assignee Address: FR Les Ulis
- Agency: Foley & Lardner LLP
- Priority: FR0309440 20030731
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
Public/Granted literature
- US20100303826A1 Use of ADCC-Optimized antibodies for treating weak patients Public/Granted day:2010-12-02
Information query
